Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Spvn06

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1/2 (2)

Trial Status

Unknown2
Completed1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT05748873Phase 1/2Active Not Recruiting

Promising ROd-cone DYstrophy Gene therapY

NCT03872479Phase 1/2Unknown

Single Ascending Dose Study in Participants With LCA10

NCT01876147Completed

Visual and Functional Assessment in Low Vision Patients

NCT03691168UnknownPrimary

Multi-center Observation of the Natural Course of Inherited Retinal Dystrophies

Showing all 4 trials

Research Network

Common Treatments

  • Spvn061
  • Edit1011

Active Sponsors

  • SparingVision1
  • University of Oxford1
  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine1
  • Editas Medicine, Inc.1

Top Investigators

Related Conditions

  • Retinitis Pigmentosa2
  • Leber Congenital Amaurosis 101
  • Agerelated Macular Degeneration1
  • Retinal Disease1
  • Eye Disorders Congenital1

Activity Timeline